Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been assigned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $6.23.

Several research analysts have commented on the company. Jefferies Financial Group upgraded Ironwood Pharmaceuticals to a “hold” rating in a report on Friday, September 25th. Wall Street Zen cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 5th. Weiss Ratings upgraded Ironwood Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Finally, Zacks Research downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th.

Ironwood Pharmaceuticals Price Performance

Ironwood Pharmaceuticals stock opened at $3.56 on Tuesday. The stock has a market cap of $588.25 million, a price-to-earnings ratio of 4.49 and a beta of 0.21. Ironwood Pharmaceuticals has a 1 year low of $1.44 and a 1 year high of $5.78. The firm has a 50-day moving average of $4.09 and a two-hundred day moving average of $3.98.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%. The firm had revenue of $113.04 million during the quarter, compared to analysts’ expectations of $114.84 million. Research analysts expect that Ironwood Pharmaceuticals will post 1.10 earnings per share for the current year.

Institutional Trading of Ironwood Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. CWA Asset Management Group LLC boosted its stake in shares of Ironwood Pharmaceuticals by 71.7% during the third quarter. CWA Asset Management Group LLC now owns 498,643 shares of the biotechnology company’s stock valued at $1,980,000 after purchasing an additional 208,277 shares in the last quarter. State of Alaska Department of Revenue purchased a new position in Ironwood Pharmaceuticals during the third quarter valued at approximately $239,000. Engineers Gate Manager LP increased its holdings in Ironwood Pharmaceuticals by 22.8% during the second quarter. Engineers Gate Manager LP now owns 98,052 shares of the biotechnology company’s stock valued at $413,000 after buying an additional 18,200 shares during the period. Squarepoint Ops LLC raised its stake in Ironwood Pharmaceuticals by 104.3% in the second quarter. Squarepoint Ops LLC now owns 66,899 shares of the biotechnology company’s stock worth $282,000 after buying an additional 34,153 shares in the last quarter. Finally, AXQ Capital LP raised its stake in Ironwood Pharmaceuticals by 263.2% in the second quarter. AXQ Capital LP now owns 47,028 shares of the biotechnology company’s stock worth $198,000 after buying an additional 34,079 shares in the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused biopharmaceutical company that discovers, develops, and commercializes medicines for gastrointestinal diseases. The company concentrates on conditions affecting the digestive system, including disorders with substantial unmet medical needs.

Ironwood’s principal commercial product is LINZESS (linaclotide), a prescription treatment for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. In the United States, LINZESS is marketed through a collaboration with AbbVie, while it is marketed in many international markets under the name CONSTELLA through a collaboration with the healthcare business of AstraZeneca and other regional partners.

Founded in 1998 and headquartered in Boston, Massachusetts, Ironwood has expanded its development activities through internal research, partnerships, and acquisitions.